GMP inspection for the facility and new products was completed.
Pharmigene’s HLA-B*5801 Assessment Test received approval from the Department of Health, Taiwan.
A new manufacturing plant was built, and the headquarter relocated to Taipei (Neihu).
ISO / CE IVD 2012 annual inspection was completed.
Pharmigene’s HLA-B*5701/3101 received IVD List B CE certification (Verification Unit: SGS)
